SCHEMBL5757614

SCHEMBL5757614

O=C(O)c1c[nH]c(=O)n(-c2cccc(C(F)(F)F)c2)c1=O

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 3/20 0.56
ALKBH5 Q6P6C2 1/20 0.50
CYP1A2 P05177 3/20 0.48
KMT2A Q03164 3/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
ALOX12 P18054 1/20 0.46
HTT P42858 1/20 0.45
POLB P06746 2/20 0.44
GAA P10253 1/20 0.43
PLA2G10 O15496 1/20 0.43
CCKBR P32239 1/20 0.42
CYP2C19 P33261 1/20 0.42
CFTR P13569 1/20 0.42
ELANE P08246 1/20 0.41
AR P10275 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5930954 0.89 PLA2G10 (0.50) NOTUMALKBH5CYP1A2KMT2AMEN1
SCHEMBL23882395 0.80 CYP2C19 (0.58) NOTUMCYP1A2KMT2AMEN1ALDH1A1
SCHEMBL17819292 0.80 CYP1A2 (0.60) NOTUMALKBH5CYP1A2KMT2AMEN1
SCHEMBL5760660 0.79 ELANE (0.55) CYP1A2KMT2AMEN1ALDH1A1HPGD
SCHEMBL5757809 0.79 ELANE (0.55) KMT2AMEN1HPGDPOLBELANE
SCHEMBL5752612 0.78 NOTUM (0.76) NOTUMALKBH5CYP1A2ALDH1A1POLB
SCHEMBL29808797 0.78 NOTUM (0.76) NOTUMALKBH5CYP1A2ALDH1A1POLB
SCHEMBL561046 0.78 NOTUM (0.68) NOTUMALKBH5CYP1A2KMT2AMEN1
SCHEMBL5759381 0.78 LMNA (0.56) CYP1A2KMT2AMEN1HPGDHTT
SCHEMBL4093082 0.77 CYP1A2 (0.51) NOTUMALKBH5CYP1A2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed
CN-1711243-A 2-pyridone derivatives as inhibitors of neutrophil elastase ASTRAZENECA AB (SE) 2005-12-21 CN disclosed
EP-1562902-A1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE AstraZeneca AB (SE) 2005-08-17 EP disclosed
WO-2004043924-A1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 NOTUM 3748/4885ALKBH5 4677/4885CYP1A2 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.